Compare Bristol-Myers Squibb Co (BMY) vs Coupang Inc (CPNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Coupang Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.55 (market cap $116.30B), while Coupang Inc trades at $17.91 (market cap $32.17B). The key difference: Bristol-Myers Squibb Co is far larger — about 3.6× Coupang Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Coupang Inc pays none. Which is the better fit depends on your goals.
| BMY | CPNG | |
|---|---|---|
Market Cap | $116.30B | $32.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $62.37 | $33.53 |
52-Week Low | $42.60 | $15.12 |
Enterprise Value | $152.24B | $31.26B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
CPNG trades at $17.92, down 4.68% today, with a bearish technical signal and mixed earnings. Revenue grew to $34.53B in 2025, but net income margin is negative at -0.47%. Recent news includes a $412M fine for a data breach in South Korea (Reuters, 2026-06-11). The stock faces regulatory headwinds but maintains strong analyst support with an 87.5% buy rating and a $25.80 consensus target.
Outlook: CPNG offers growth potential from e-commerce expansion but carries risks from regulatory fines and profitability challenges. Investors should weigh strong cash flow against recent earnings misses and legal issues. The stock's current price is 30% below the consensus target, presenting upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Coupang Inc
Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.
Read more on CPNG →
